MX2020002243A - Anticuerpos utiles en diagnosis de cancer. - Google Patents

Anticuerpos utiles en diagnosis de cancer.

Info

Publication number
MX2020002243A
MX2020002243A MX2020002243A MX2020002243A MX2020002243A MX 2020002243 A MX2020002243 A MX 2020002243A MX 2020002243 A MX2020002243 A MX 2020002243A MX 2020002243 A MX2020002243 A MX 2020002243A MX 2020002243 A MX2020002243 A MX 2020002243A
Authority
MX
Mexico
Prior art keywords
cancer diagnosis
useful antibodies
useful
cldn6
diagnosis
Prior art date
Application number
MX2020002243A
Other languages
English (en)
Other versions
MX393242B (es
Inventor
Korden Walter
Stefan Wöll
Rita Mitnacht-Kraus
Özlem Türeci
Ugur Sahin
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2020002243A publication Critical patent/MX2020002243A/es
Publication of MX393242B publication Critical patent/MX393242B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/91—Cell lines ; Processes using cell lines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a anticuerpos dirigidos contra un epítopo ubicado dentro de la porción C-terminal de CLDN6 que son útiles, por ejemplo, en el diagnóstico de cáncer y/o en la determinación de si las células de cáncer expresan CLDN6.
MX2020002243A 2017-09-06 2018-09-05 Anticuerpos utiles en diagnosis de cancer MX393242B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2017/072386 WO2019048040A1 (en) 2017-09-06 2017-09-06 ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER
PCT/EP2018/073883 WO2019048489A1 (en) 2017-09-06 2018-09-05 ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER

Publications (2)

Publication Number Publication Date
MX2020002243A true MX2020002243A (es) 2020-07-20
MX393242B MX393242B (es) 2025-03-24

Family

ID=59858709

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020002243A MX393242B (es) 2017-09-06 2018-09-05 Anticuerpos utiles en diagnosis de cancer
MX2022007706A MX2022007706A (es) 2017-09-06 2020-02-27 Anticuerpos utiles en diagnosis de cancer.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022007706A MX2022007706A (es) 2017-09-06 2020-02-27 Anticuerpos utiles en diagnosis de cancer.

Country Status (15)

Country Link
US (3) US11279757B2 (es)
EP (2) EP3679069B1 (es)
JP (2) JP7277439B2 (es)
KR (2) KR20230107371A (es)
CN (3) CN111406070A (es)
AU (2) AU2018327587B2 (es)
BR (1) BR112020003694B1 (es)
CA (1) CA3073157A1 (es)
ES (1) ES2998108T3 (es)
IL (2) IL293017A (es)
MX (2) MX393242B (es)
PL (1) PL3679069T3 (es)
SG (1) SG11202000961SA (es)
WO (2) WO2019048040A1 (es)
ZA (1) ZA202000851B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2404936A1 (en) * 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
WO2019048040A1 (en) 2017-09-06 2019-03-14 Ganymed Pharmaceuticals Gmbh ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER
SG11202001430SA (en) 2017-09-29 2020-04-29 Daiichi Sankyo Co Ltd Antibody-pyrrolobenzodiazepine derivative conjugate
MA54955A (fr) 2019-02-15 2021-12-22 Integral Molecular Inc Anticorps anti-claudine 6 et leurs utilisations
CN117222672A (zh) 2021-04-22 2023-12-12 安斯泰来制药株式会社 抗cldn4-抗cd137双特异性抗体
EP4626933A1 (en) 2022-11-30 2025-10-08 Integral Molecular, Inc. Antibodies directed to claudin 6, including bispecific formats thereof
CN121793985A (zh) 2023-05-25 2026-04-03 加利福尼亚大学校董会 治疗癌症的方法
WO2025146161A1 (en) * 2024-01-04 2025-07-10 Hansoh Bio Llc Antibody, antigen-binding fragment and medical use thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
IL155977A0 (en) 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
KR20110017020A (ko) 2002-10-17 2011-02-18 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
EP1668035A2 (en) * 2003-09-11 2006-06-14 Critical Therapeutics, Inc. Monoclonal antibodies against hmgb1
WO2008013948A2 (en) * 2006-07-27 2008-01-31 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
NZ601022A (en) * 2006-10-12 2014-09-26 Chugai Pharmaceutical Co Ltd Diagnosis and treatment of cancer using anti-ereg antibody
WO2009028663A1 (ja) * 2007-08-30 2009-03-05 Kyowa Hakko Kirin Co., Ltd. 抗Claudin-3抗体
US9274119B2 (en) 2008-01-11 2016-03-01 The University Of Tokyo Anti-CLDN6 antibody
EP2322555A1 (en) * 2009-11-11 2011-05-18 Ganymed Pharmaceuticals AG Antibodies specific for claudin 6 (CLDN6)
RU2675997C2 (ru) * 2009-11-11 2018-12-25 Ганимед Фармасьютикалз Аг Антитела, специфичные к клаудину 6 (cldn6)
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
RS58087B1 (sr) * 2011-05-13 2019-02-28 Ganymed Pharmaceuticals Gmbh Antitela za lečenje kancera koji eksprimira klaudin 6
WO2015014376A1 (en) * 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
GB201607534D0 (en) * 2016-04-29 2016-06-15 Immunocore Ltd & Adaptimmune Ltd Peptides
WO2019048040A1 (en) 2017-09-06 2019-03-14 Ganymed Pharmaceuticals Gmbh ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER

Also Published As

Publication number Publication date
IL272487A (en) 2020-03-31
SG11202000961SA (en) 2020-02-27
KR20230107371A (ko) 2023-07-14
ES2998108T3 (en) 2025-02-19
US20200199221A1 (en) 2020-06-25
US20220162302A1 (en) 2022-05-26
KR20200040784A (ko) 2020-04-20
WO2019048489A1 (en) 2019-03-14
US11919951B2 (en) 2024-03-05
US11279757B2 (en) 2022-03-22
WO2019048040A1 (en) 2019-03-14
JP2020532572A (ja) 2020-11-12
BR112020003694A2 (pt) 2020-09-08
KR102550489B1 (ko) 2023-07-03
JP2023103315A (ja) 2023-07-26
AU2023208203A1 (en) 2023-08-17
EP3679069A1 (en) 2020-07-15
IL272487B (en) 2022-06-01
ZA202000851B (en) 2021-08-25
CN115433283B (zh) 2024-05-24
CA3073157A1 (en) 2019-03-14
CN118852435A (zh) 2024-10-29
PL3679069T3 (pl) 2025-03-24
CN115433283A (zh) 2022-12-06
EP4512830A3 (en) 2025-05-21
JP7277439B2 (ja) 2023-05-19
EP3679069B1 (en) 2024-11-20
AU2018327587B2 (en) 2023-05-04
NZ761712A (en) 2025-08-29
AU2018327587A1 (en) 2020-03-05
CN111406070A (zh) 2020-07-10
EP4512830A2 (en) 2025-02-26
IL293017A (en) 2022-07-01
US20240209079A1 (en) 2024-06-27
MX2022007706A (es) 2022-07-19
MX393242B (es) 2025-03-24
EP3679069C0 (en) 2024-11-20
BR112020003694B1 (pt) 2024-03-12

Similar Documents

Publication Publication Date Title
CL2019000100A1 (es) Anticuerpos contra tim3 y suso de los mismos.
MX2022000132A (es) Inmunoreceptores especificos de claudina-18.2 y epitopos de celulas t.
CY1122676T1 (el) Αντισωματα εναντι της κλαυδινης 18.2 που ειναι χρησιμα στη διαγνωση του καρκινου
MX2022007706A (es) Anticuerpos utiles en diagnosis de cancer.
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
MA40576B1 (fr) Anticorps et immunoconjugués anti-her2
ECSP17001673A (es) Anticuerpos monoclonales contra el epitope de her2
CO2019013654A2 (es) Receptores de antígenos quiméricos que se dirigen a flt3
SV2019005807A (es) Anticuerpos específicos para la tau hiperfosforilada y sus métodos de uso
MX382582B (es) Anticuerpos contra cúmulo de diferenciación 48 (cd48) y sus conjugados.
CO2017006740A2 (es) Anticuerpos anti–cd79b
CR20170251A (es) Anticuerpos anti-c5 y métodos para su uso
EA201591465A1 (ru) Специфичные участки для модификации антител для получения иммуноконъюгатов
MX2016013239A (es) Tratamiento de cancer utilizando receptor quimerico de antigeno anti-cd19.
MX376026B (es) Inmunoreceptores especificos de claudina-6 y epitopos de celulas t.
MX2017000419A (es) Anticuerpos anti-pd-l1 y sus usos de diagnóstico.
BR112018003339A8 (pt) Anticorpos antimesotelina completamente humanos e células imunoefetoras que direcionam mesotelina
AR103726A1 (es) Cristales de anticuerpos monoclonales anti-pd-1 humanos
MX2016012124A (es) Anticuerpos contra glicopeptidos inmunogenicos, composicion que los comprende y usos de estos.
ES3052034T3 (en) Humanized or chimeric cd3 antibodies
EP3705494A3 (en) Antibodies against frizzled proteins and methods of use thereof
JO3791B1 (ar) تركيبات و طرق الأجسام المضادة المستهدفة لـ bmp6
MX392040B (es) Estandares de antigeno prostatico y sus usos.
MX2014013678A (es) Agentes para neutralizacion de influenza.
MX382809B (es) Uso de tm9sf4 como un biomarcador para exosomas asociadas con tumores.